ATE192045T1 - Verwendung von substituierten adeninderivaten zur behandlung von multiplesklerose - Google Patents

Verwendung von substituierten adeninderivaten zur behandlung von multiplesklerose

Info

Publication number
ATE192045T1
ATE192045T1 AT93906071T AT93906071T ATE192045T1 AT E192045 T1 ATE192045 T1 AT E192045T1 AT 93906071 T AT93906071 T AT 93906071T AT 93906071 T AT93906071 T AT 93906071T AT E192045 T1 ATE192045 T1 AT E192045T1
Authority
AT
Austria
Prior art keywords
multiple sclerosis
treatment
adenine derivatives
substituted adenine
formula
Prior art date
Application number
AT93906071T
Other languages
English (en)
Inventor
Ernest Beutler
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE192045T1 publication Critical patent/ATE192045T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT93906071T 1992-02-19 1993-02-18 Verwendung von substituierten adeninderivaten zur behandlung von multiplesklerose ATE192045T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/838,546 US5310732A (en) 1986-02-03 1992-02-19 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
PCT/US1993/001467 WO1993016706A1 (en) 1992-02-19 1993-02-18 Use of substituted adenine derivatives for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
ATE192045T1 true ATE192045T1 (de) 2000-05-15

Family

ID=25277387

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93906071T ATE192045T1 (de) 1992-02-19 1993-02-18 Verwendung von substituierten adeninderivaten zur behandlung von multiplesklerose

Country Status (15)

Country Link
US (4) US5310732A (de)
EP (1) EP0626853B1 (de)
JP (1) JP2688113B2 (de)
AT (1) ATE192045T1 (de)
AU (1) AU682818B2 (de)
BR (1) BR9305907A (de)
CA (1) CA2130275C (de)
CH (1) CH684310A5 (de)
DE (1) DE69328474T2 (de)
DK (1) DK0626853T3 (de)
FI (1) FI943805A7 (de)
HU (1) HU218656B (de)
NO (2) NO309025B1 (de)
RU (1) RU2130308C1 (de)
WO (1) WO1993016706A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5624913A (en) * 1991-04-05 1997-04-29 Wisconsin Alumni Research Foundation Method reducing TNF-alpha in mammals with cerebral malaria
EP0642347A4 (de) * 1992-05-19 1997-06-18 Scripps Research Inst Verwendung von 2-halo-adeninderivaten als therapeutische wirkstoffe gegen chronisch-myeloische leukämie.
US5424296A (en) * 1993-04-15 1995-06-13 The Scripps Research Institute 2-Halo-2'-deoxyadenosines as therapeutic agents against malignant astrocytoma
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US5773570A (en) * 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
US7094597B1 (en) * 1994-05-20 2006-08-22 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
WO1995032718A1 (en) * 1994-05-26 1995-12-07 The Scripps Research Institute 2-halo-2'-deoxyadenosine treatement for inflammatory bowel disease
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
WO1996003134A1 (en) * 1994-07-21 1996-02-08 Thomas Jefferson University Treatment of diarrhea with 2-substituted adenosine derivatives
US5510336A (en) * 1994-09-06 1996-04-23 Saven; Alan 2-halo-2'-deoxyadenosine treatment for histiocytosis
US5641757A (en) * 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
AU762821B2 (en) * 1994-12-22 2003-07-03 Ortho-Mcneil Pharmaceutical, Inc. 'Soluble 2-chloro-2'-deoxyadenosine formulations'
PT801571E (pt) * 1994-12-22 2002-12-31 Ortho Pharma Corp Formulacoes soluveis de 2-cloro-2'-desoxiadenosina
CN1173818A (zh) * 1995-02-10 1998-02-18 舍林股份公司 用于tnf抑制的药物制剂
US5811073A (en) * 1995-06-19 1998-09-22 President And Fellows Of Harvard College Method for radioisotopic detection and localization of inflammation in a host
US6096310A (en) * 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6174873B1 (en) 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
EP1200102A1 (de) * 1999-07-22 2002-05-02 Supergen, Inc. Verfahren zur behandlung von autoimmunerkrankungen
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
AU3851601A (en) * 2000-02-18 2001-08-27 Southern Res Inst Methods for synthesizing 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-9h- purin-6-amine
SE516067C2 (sv) * 2000-02-18 2001-11-12 Lundblad Leif J I Användning av en förening för framställning av ett läkemedel
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US7608683B2 (en) * 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
EA005821B1 (ru) 2000-11-01 2005-06-30 Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния Иммуномодулирующие пептиды, полученные из белков теплового шока, и их применение
WO2002078446A1 (en) * 2001-03-29 2002-10-10 Bioenergy Inc. Composition to reduce exercise-induced swelling of joints
US7528247B2 (en) * 2001-08-02 2009-05-05 Genzyme Corporation Process for preparing purine nucleosides
US7368423B1 (en) * 2001-12-05 2008-05-06 The Scripps Research Institute Composition and method for treating chronic allograft rejection
US20060100167A1 (en) * 2002-09-27 2006-05-11 Wood Christopher B Methods and compositions for the treatment of autoimmune disorders using clofarabine
AU2003276987B2 (en) * 2002-09-27 2009-07-30 Bioenvision, Inc. Methods and compositions for the treatment of lupus using clofarabine
US20080221029A1 (en) * 2002-10-31 2008-09-11 Regents Of The University Of Colorado Methods for treatment of thiol-containing compound deficient conditions
US20040087527A1 (en) * 2002-10-31 2004-05-06 Day Brian J. Methods for treatment of thiol-containing compound deficient conditions
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
GB0228723D0 (en) * 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305153D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
KR101129816B1 (ko) * 2003-03-28 2012-03-26 아레스 트레이딩 에스.아. 클라드리빈의 경구용 제형
KR20060011943A (ko) * 2003-03-28 2006-02-06 아이박스 코포레이션 향상된 경구 및 경점막 수송용 클라드리빈 제형
UA81305C2 (en) 2003-07-02 2007-12-25 Ares Trading Sa Formulation of cladribine (variants), cladribine-cyclodextrin complex, use of cladribine-cyclodextrin complex, mixture
CN100471842C (zh) * 2003-07-24 2009-03-25 安斯泰来制药有限公司 喹诺酮衍生物或其盐
US20070167353A1 (en) * 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
PL1699459T3 (pl) * 2003-12-29 2007-12-31 Can Fite Biopharma Ltd Sposób leczenia stwardnienia rozsianego
EP1706424B1 (de) 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Varianten der fc-region
US20050277615A1 (en) * 2004-05-17 2005-12-15 Can-Fite Biopharma Ltd. Pharmaceutical compositions having anti-inflammatory activity
DK2805723T3 (da) * 2004-12-22 2018-01-29 Merck Serono Sa Cladribin-regime til behandling af multipel sclerose
WO2006067134A1 (en) * 2004-12-22 2006-06-29 Laboratoires Serono S.A. Combination treatment for multiple sclerosis
US8658622B2 (en) * 2005-01-14 2014-02-25 Regents Of The University Of California Methods and compositions for preventing and treating a disease related to glycan dysregulation
RU2393866C2 (ru) * 2005-03-17 2010-07-10 Проекто Де Биомедисина Сима, С.Л. Применение 5'-метилтиоаденозина (мта) для предотвращения и/или лечения аутоиммунных заболеваний и/или отторжения трансплантата
MX2008014971A (es) 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.
US8126690B2 (en) * 2007-05-18 2012-02-28 The Regents Of The University Of Michigan Algorithms to predict clinical response, adherence, and shunting with thiopurines
EP2030615A3 (de) * 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonukleotidreduktase-Inhibitoren zur Verwendung für die Behandlung oder Vorbeugung von Nervenentzündung- oder Autoimmunerkrankungen
US8845627B2 (en) 2008-08-22 2014-09-30 Boston Scientific Scimed, Inc. Regulating pressure to lower temperature in a cryotherapy balloon catheter
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
EP2343074A1 (de) 2009-12-23 2011-07-13 Merck Serono S.A. Verwendung von Purinanaloga zur Behandlung von Atemwegserkrankungen
WO2012022740A1 (en) 2010-08-18 2012-02-23 Merck Serono S.A. Combination treatment of multiple sclerosis
CN105247042B (zh) 2013-03-15 2021-06-11 普林斯顿大学理事会 用于高通量纯化的方法和设备
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
CN110186835B (zh) 2013-03-15 2022-05-31 Gpb科学有限公司 颗粒的片上微流体处理
GB201401465D0 (en) 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
WO2016073897A1 (en) 2014-11-06 2016-05-12 Northwestern University Inhibition of cancer cell motility
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
EP3341893A4 (de) * 2015-08-24 2019-03-06 GPB Scientific, LLC Verfahren und vorrichtungen zur mehrstufigen zellreinigung und -konzentration
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
CN111356460A (zh) 2017-11-24 2020-06-30 默克专利股份公司 用于治疗进展型形式的多发性硬化症的克拉屈滨疗法
CA3194812A1 (en) 2020-09-10 2022-03-17 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
US20240077481A1 (en) 2021-03-03 2024-03-07 Ares Trading S.A. Improved treatment methods using dmds for the treatment of autoimmune diseases, and biomarker for predicting and/or optimising said treatment methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1572070C3 (de) * 1966-03-12 1979-03-22 Hoechst Ag, 6000 Frankfurt Lichtempfindliches Kopiermaterial
US3472838A (en) * 1967-12-01 1969-10-14 Parke Davis & Co 9 - (beta - d - arabinofuranosyl) - 6 - (amidino) purine compounds and methods for their production
US4826823A (en) * 1985-02-05 1989-05-02 Warner-Lambert Company Methods of using 2-chloro-2'-deoxyadenosine-5'-phosphate and its salts
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
GB8708050D0 (en) * 1987-04-03 1987-05-07 Wellcome Found Therapeutic nucleosides
GB8725466D0 (en) 1987-10-30 1987-12-02 Hoffmann La Roche Purine derivatives
EP0314011A3 (de) * 1987-10-30 1990-04-11 F. Hoffmann-La Roche Ag Purinderivate
KR0138996B1 (ko) * 1988-03-16 1998-04-30 레이몬드 에이치. 칸 치환된 아데닌 유도체 및 이를 함유하는 약제학적 조성물
US4968702A (en) * 1989-01-17 1990-11-06 American Cyanamid Company Substituted quinolinecarboxylic acids

Also Published As

Publication number Publication date
FI943805L (fi) 1994-10-19
NO20000762L (no) 1994-09-13
US5310732A (en) 1994-05-10
BR9305907A (pt) 1997-10-21
HU218656B (hu) 2000-10-28
AU682818B2 (en) 1997-10-23
NO942765D0 (no) 1994-07-25
WO1993016706A1 (en) 1993-09-02
AU3724993A (en) 1993-09-13
EP0626853A1 (de) 1994-12-07
DE69328474T2 (de) 2000-09-28
US5506213A (en) 1996-04-09
CA2130275A1 (en) 1993-09-02
JP2688113B2 (ja) 1997-12-08
HUT68030A (en) 1995-05-29
EP0626853B1 (de) 2000-04-26
NO942765L (no) 1994-09-13
US5506214A (en) 1996-04-09
NO309025B1 (no) 2000-12-04
FI943805A0 (fi) 1994-08-18
NO20000762D0 (no) 2000-02-16
CA2130275C (en) 1999-06-29
HU9402392D0 (en) 1994-10-28
US5541164A (en) 1996-07-30
NO322328B1 (no) 2006-09-18
RU2130308C1 (ru) 1999-05-20
RU94038043A (ru) 1996-11-20
JPH07507540A (ja) 1995-08-24
FI943805A7 (fi) 1994-10-19
CH684310A5 (de) 1994-08-31
DE69328474D1 (de) 2000-05-31
DK0626853T3 (da) 2000-08-07

Similar Documents

Publication Publication Date Title
ATE192045T1 (de) Verwendung von substituierten adeninderivaten zur behandlung von multiplesklerose
DE69630214D1 (de) Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69109125D1 (de) Ringverknüpfte analoge von stickstoffenthaltenden nichtaromatischen heterocyclen.
ATE194593T1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
FI941022A0 (fi) Spirosykliset piperidiinijohdannaiset
ES533338A0 (es) Derivados de la 2-pirimidinil-1-piperazina
DK0636025T3 (da) Forbindelser, der er egnede til behandling af allergiske og inflammatoriske sygdomme
DK165003C (da) Chlorsulfat
ATE250576T1 (de) Substituierte pyrrolylverbindungen zur behandlung von entzündungen
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
KR900700495A (ko) 치료제로서 유용한 치환된 아데닌 유도체
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
YU13499A (sh) Primena 1-hidroksi-2-piridona za lečenje seboroitičnog dermatitisa
DE69432626D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen
ATE114468T1 (de) Ethyl-(+)-apovincaminat zur behandlung der demyelinisierung klinischer erscheinungen autoimmunen ursprungs.
ATE71620T1 (de) N-substituierte 3,4-dihydropyrimidinverbindungen als mittel zur behandlung von erkrankungen des kardiovaskularen systems.
RU94038063A (ru) 3-фенилуреидо-азепин-2-оны и -бензазепин-2-оны, способы их получения, промежуточные соединения, фармацевтические композиции и способы лечения
ATE208202T1 (de) Verwendung von dimeticon zur behandlung der konstipation
ATE357914T1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
DE69623767D1 (de) Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus
DE59101581D1 (de) Verwendung von efeu zur topischen behandlung der psoriasis.
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
ATE269090T1 (de) Tiermodell zum testen von arzneistoffen zur behandlung von leukämie oder hiv
DE69802828D1 (de) Verwendung von 6,7-substituierter 2-aminotetraline zur behandlung von zytokin-vermittleten entzündungszuständen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties